Table 3 Discounted and undiscounted incremental lifetime effects of ERT versus no ERT treatment, overall and by gender (YFEOD: years free of end-organ damage; QALYs: quality adjusted life-years)
From: Cost-effectiveness of enzyme replacement therapy for Fabry disease
Discount rate 1.5% | Discount rate 0% | |||||
|---|---|---|---|---|---|---|
ERT | No ERT | Difference | ERT | No ERT | Difference | |
ALL | ||||||
YFEOD | 36.9 | 36.1 | 0.7 | 56.5 | 55.0 | 1.5 |
QALYs | 32.1 | 31.3 | 0.7 | 50.2 | 48.6 | 1.6 |
MALES | ||||||
YFEOD | 36.2 | 35.4 | 0.8 | 55.1 | 53.5 | 1.6 |
QALYs | 31.7 | 30.9 | 0.8 | 49.5 | 47.8 | 1.7 |
FEMALES | ||||||
YFEOD | 37.7 | 37.1 | 0.6 | 58.2 | 56.9 | 1.3 |
QALYs | 32.6 | 31.9 | 0.7 | 51.1 | 49.7 | 1.4 |